In Depth 10 Mar 2021
Can Gene Therapy Cure Blindness?
Since the approval of the first gene therapy for blindness, there has been a wave of companies developing gene therapy treatments with the potential to cure different forms of genetic…
Eyevensys
- Latest Posts
Expert Advice 24 Aug 2020
Why a US Presence Can Help European Biotechs Get Ahead
While there is no doubt that Europe has a thriving biotech scene, it can really help a European company to succeed if it has a US presence. No one knows…
News and Trends 10 Jan 2020
Eyevensys’ Gene Therapy for Blindness Boosted with €27M Series B
The French company Eyevensys has raised €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis…
In Depth 28 Nov 2017
Reviewing Gene Therapy: How Close is Biotech to Genetic Cures?
Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix each of them. Here's a review of biotech's progress. Biotech is arguably built on genetic…
ADVERTISEMENT
News and Trends 15 May 2017
German Biotech Clears Phase I with New Gene Therapy for Glaucoma
Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β…
Interview 11 May 2017
Video: Meet the CEO developing Gene Therapy without Viral Vectors
Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company's CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris…
News and Trends 11 Apr 2017
France Approves Trials for the First Eye Gene Therapy Free of Viral DNA
Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared…
